Resources
evidence-data· 20 May 2026· 11 min read
Synthetic control arms: when regulators actually buy them
Not as often as the press releases suggest.
Author
Chief Innovation Officer
Where SCAs land
Synthetic control arms work best where a randomised comparator is genuinely infeasible, the external data is high-quality and contemporaneous, and the natural history of the disease is well-characterised. Outside that envelope, regulators ask for the trial you should have run.
Illustrative acceptance signal by setting
HTA is harder than regulatory
A regulator may accept an SCA for approval. A HTA body may still demand a comparative analysis for reimbursement. Plan the SCA for both audiences.
Sources